{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:05:08Z","timestamp":1784019908671,"version":"3.55.0"},"reference-count":43,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Almirall S.p.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Psoriasis is a chronic inflammatory skin disease leading to substantial psycho-physical and social burden and reduced quality of life. Biologic agents have transformed its therapeutic landscape. This real-world Italian study described the pattern of treatment with biologic drugs in patients with psoriasis. Methods: A retrospective observational study was conducted using administrative databases from Italian Local Health Units, covering nearly 12 million individuals. The study included adults with psoriasis identified from January 2015 to March 2025 by hospitalization, co-payment exemption code, or topical anti-psoriatic prescriptions. Patients initiating a biologic drug (anti-TNF\u03b1, anti-IL12\/23, anti-IL17, and anti-IL23) were selected and further analyzed in terms of treatment switching, drug survival, and healthcare resource utilization and related costs within the first year after biologic initiation, and compared. Results: A total of 10,270 biologic-na\u00efve adult patients was included in the analysis (anti-TNF\u03b1 N = 5078; anti-IL12\/23 N = 767; anti-IL17 N = 2574; anti-IL23 N = 1851). Most patients (95.0%) starting an anti-IL23 agent did not switch. Compared with anti-TNF\u03b1, initiating an anti-IL23 inhibitor was associated with a significant reduced risk of switching (HR = 0.186; 95%CI: 0.144\u20130.240; p &lt; 0.001). According to the cost analysis stratified by switching status, remaining on the index biologic was associated with a lower economic burden. Although differences between switchers vs. non-switchers among anti-IL23 users did not reach statistical significance (\u20ac12,052 vs. \u20ac11,406, respectively, p = 0.132), data support the economic advantage associated with greater treatment stability. Conclusions: Anti-IL23 agents showed effective, durable first-line use with potential long-term clinical and economic benefits in moderate-to-severe psoriasis.<\/jats:p>","DOI":"10.3390\/jcm15145509","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:04:31Z","timestamp":1784016271000},"page":"5509","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Switching and Drug Survival of Biologic Therapies in Psoriasis: A Real-World Italian Study Across Biologic Classes"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9345-2855","authenticated-orcid":false,"given":"Silvia","family":"Calabria","sequence":"first","affiliation":[{"name":"CliCon S.r.l. Societ\u00e0 Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37129 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3070-4071","authenticated-orcid":false,"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo Giovanni","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Research Centre on Public Health, University of Milano-Bicocca, 20900 Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-2022","authenticated-orcid":false,"given":"Chiara","family":"Veronesi","sequence":"additional","affiliation":[{"name":"CliCon S.r.l. Societ\u00e0 Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-6659","authenticated-orcid":false,"given":"Luca","family":"Degli Esposti","sequence":"additional","affiliation":[{"name":"CliCon S.r.l. Societ\u00e0 Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Xiong, J., Xue, T., Tong, M., Xu, L., and Bai, B. (2025). Dynamic trend analysis of global psoriasis burden from 1990 to 2021: A study of gender, age, and regional differences based on GBD 2021 data. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1518681"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102193","DOI":"10.1016\/j.eclinm.2023.102193","article-title":"Global, regional, and national incidence of six major immune-mediated inflammatory diseases: Findings from the global burden of disease study 2019","volume":"64","author":"Wu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000075044","article-title":"Study design and preliminary results from the pilot phase of the PraKtis study: Self-reported diagnoses of selected skin diseases in a representative sample of the Italian population","volume":"208","author":"Naldi","year":"2004","journal-title":"Dermatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: A European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PTT.S396003","article-title":"Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population","volume":"13","author":"Perrone","year":"2023","journal-title":"Psoriasis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40801-021-00290-3","article-title":"Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting","volume":"9","author":"Perrone","year":"2022","journal-title":"Drugs-Real World Outcomes"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","article-title":"Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"138","author":"Iskandar","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Ibba, L., Malagoli, P., Balato, A., Bardazzi, F., Burlando, M., Carrera, C.G., Damiani, G., Dapavo, P., and Dini, V. (2024). Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: A retrospective multicenter real-world experience on 5932 treatment courses\u2014IL PSO (Italian landscape psoriasis). Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1341708"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Di Giulio, S., Falcidia, C., Foggi, G., Bianco, M., Gargiulo, L., Valenti, M., Costanzo, A., Narcisi, A., and Ibba, L. (2025). Predictors of Super-Responder Status to Anti-IL-23 Therapies in Moderate-to-Severe Plaque Psoriasis: A Real-World Monocenter Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14186371"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/ced\/llae282","article-title":"Early intervention and cumulative life course impairment in psoriasis: A review","volume":"49","author":"Arancio","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gisondi, P., Geat, D., Maurelli, M., Degli Esposti, L., Bellinato, F., and Girolomoni, G. (2022). Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. Vaccines, 10.","DOI":"10.3390\/vaccines10050646"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"R\u00f8nholt, K., and Iversen, L. (2017). Old and New Biological Therapies for Psoriasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112297"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, Y., Cheng, Y., Cai, Y., Duan, Z., Xu, H., Huang, Y., Ma, X., Xin, X., and Yin, L. (2025). Novel Small-Molecule Treatment and Emerging Biological Therapy for Psoriasis. Biomedicines, 13.","DOI":"10.3390\/biomedicines13040781"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_19","unstructured":"(2026, May 22). Farmadati Italia [Internet]. Available online: https:\/\/www.farmadati.it\/prodotti-e-servizi\/nuova-banca-dati-federfarma\/gallery-for-pharmacy\/."},{"key":"ref_20","unstructured":"Ministry of Health (2026, May 22). DECREE of 18 October 2012. \u201cRemuneration of Hospital Care Services for Acute Conditions, Hospital Rehabilitation Care and Post-Acute Long-Term Care, and Outpatient Specialist Care\u201d (Official Gazette\u2013General Series No. 23 of 28 January 2013\u2013Ordinary Supplement No. 8) [Internet]. Available online: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2013\/01\/28\/13A00528\/sg."},{"key":"ref_21","unstructured":"(2026, May 22). National Fee Schedule 2017\u2013Official Prime Ministerial Decree [Internet], Available online: https:\/\/www.salute.gov.it\/new\/it\/tema\/programmazione-e-finanziamento-del-ssn\/tariffari-nazionali-delle-prestazioni-del-ssn\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study","volume":"23","author":"Torres","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_23","first-page":"34","article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment","volume":"22","author":"Mastorino","year":"2024","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/PTT.S533005","article-title":"Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study","volume":"15","author":"Mortato","year":"2025","journal-title":"Psoriasis Targets Ther."},{"key":"ref_26","unstructured":"ITALIAN MEDICINES AGENCY (AIFA) (2026, May 22). Decree of 23 January 2020 Reclassification of the Medicinal Product for Human Use \u201cIlumetri.\u201d (Decree No. 99\/2020). (20A00776) (Official Gazette, General Series No. 34 of 11-02-2020). [Internet]. Available online: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2020\/02\/11\/20A00776\/sg."},{"key":"ref_27","unstructured":"ITALIAN MEDICINES AGENCY (AIFA) (2026, May 22). Decree of 18 April 2023 Reclassification of the Medicinal Product for Human Use \u201cIlumetri.\u201d (Decree No. 279\/2023). (23A02486) (Official Gazette, General Series No. 101 of 02-05-2023). [Internet]. Available online: https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2023-05-02&atto.codiceRedazionale=23A02486&elenco30giorni=false."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Campione, E., Lambiase, S., Gaeta Shumak, R., Galluzzo, M., Lanna, C., Costanza, G., Borselli, C., Artosi, F., Cosio, T., and Tofani, L. (2023). A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040526"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1007\/s13555-025-01538-4","article-title":"Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical Practice","volume":"15","author":"Mateu","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2025.01.031","article-title":"Personalizing Biologic Therapy in Psoriasis: Development, Validation, and User Testing of a Precision-Dosing Dashboard","volume":"145","author":"Thomas","year":"2025","journal-title":"J. Investig. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/jdv.20739","article-title":"Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study","volume":"39","author":"Yiu","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjd.16809","article-title":"Persistence of treatment with biologics for patients with psoriasis: A real-world analysis of 16 545 biologic-na\u00efve patients from the French National Health Insurance database (SNIIRAM)","volume":"180","author":"Sbidian","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13555-021-00616-7","article-title":"Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study","volume":"11","author":"Freilich","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23736\/S2784-8671.21.07132-2","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/1346-8138.16904","article-title":"Association between cardio-cerebrovascular disease and systemic antipsoriatic therapy in psoriasis patients using population-based data: A nested case\u2013control study","volume":"50","author":"Kim","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.3748\/wjg.v22.i28.6444","article-title":"Management of psoriasis patients with hepatitis B or hepatitis C virus infection","volume":"22","author":"Bonifati","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","article-title":"Managing the Patient with Psoriasis and Metabolic Comorbidities","volume":"25","author":"Bellinato","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/bjd.16776","article-title":"Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: A multicentre longitudinal cohort study","volume":"180","author":"Warren","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/PTT.S85194","article-title":"Psoriasis and inflammatory bowel disease: Links and risks","volume":"6","author":"Bassukas","year":"2016","journal-title":"Psoriasis Targets Ther."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wang, Y., Xing, J., Liang, Y., Liang, H., Niu, X., Li, J., and Zhang, K. (2025). The complex interplay between psoriasis and depression: From molecular mechanisms to holistic treatment approaches. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1659346"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2133.2010.09944.x","article-title":"A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis: Biologic therapy: Medical resource use and costs","volume":"163","author":"Fonia","year":"2010","journal-title":"Br. J. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5509\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:18:04Z","timestamp":1784017084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":43,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145509"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145509","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}